Why this fund manager is 'very happy' to own this ASX 200 share

The ASX 200 stock has come under some selling pressure in 2023, but this fundie sees better days ahead.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index share CSL Ltd (ASX: CSL) is historically a long-term outperformer. But the stock has struggled in 2023.

Shares in the biotechnology company are currently trading for $266.80 apiece, down 5.3% since the opening bell of 3 January. That compares to a 3% gain posted by the ASX 200.

Here's why the ASX 200 share has come under pressure. And why this fund manager is "very happy" to own the biotech company.

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

What's happening with the ASX 200 share?

As you can see in the chart above, the CSL share price really hit some turbulence on 14 June.

That came after the ASX 200 share announced a downgrade of its FY 2023 profit guidance. This was driven by higher than initially forecast foreign currency headwinds.

At the time, CSL revised its forecast for its full-year net profits after tax and amortisation (NPATA) to the range of US$2.9 billion to US$3 billion in constant currency.

That revision saw the ASX 200 share close the day down 6.9%.

CSL reported its audited results on 15 August. And NPATA came in right near the bottom end of that forecast, at US$2.86 billion.

Other highlights of the FY 2023 results included a 31% increase in revenue in constant currency to US$13.31 billion. And the full-year dividend increased 6% to US$2.36 per share.

Management also reaffirmed its FY 2024 guidance. They expect NPATA of in the range of US$2.9 billion to US$3 billion in constant currency. And FY 2024 revenue growth of 9% to 11%.

Which brings us to Patrick Hodgens, managing director Firetrail Investments.

CSL counts amongst the biggest holdings at Firetrail Investments' high conviction fund.

And Hodgens wasn't put off by the ASX 200 share's results.

According to The Australian Financial Review, Firetrail believes this is a case of CEO Paul McKenzie "looking to reset".

According to Hodgens:

We're very happy to be owning CSL over the medium term and, in fact, we bought quite a bit more on the back of that perceived weakness by the market. We think CSL has some really good earnings upside if you look out two to three years.

CSL share price snapshot

As mentioned above, the CSL share price has underperformed in 2023 and over the past 12 months.

The ASX 200 share has outperformed longer-term, up 27% in five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »